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Altered mRNA expression in renal biopsy tissue from patients
with IgA nephropathy.
Background. Immunoglobulin A (IgA) nephropathy (IgAN)
is a renal disease characterized by glomerular deposition of
IgA-dominant immune deposits that cause glomerular inflam-
mation and sclerosis. Gene expression changes induced in renal
tissues/cells as a result of the disease are largely uncharacterized.
Methods. A sensitive differential mRNA display technique,
restriction endonucleolytic analysis of differentially expressed
sequences (READS) compared similarly processed normal
renal tissue to renal biopsy RNA from patients with IgAN,
minimal change disease, and necrotizing crescentic glomerulo-
nephritis. A subset of genes with altered expression in IgAN as
identified by the READS technology was further characterized
and expression levels confirmed using real-time quantitative
polymerase chain reaction (RT-PCR) analysis (TaqMan) in
all RNA.
Results. Initial READS analysis showed IgAN samples have
lower mRNA levels relative to normal renal tissue mRNA
samples based upon total RNA as measured by ribosomal
RNA. One hundred seventy-five differentially expressed non-
redundant fragments were found from 860 initial candidate
fragments. Twenty genes were selected for additional TaqMan
analysis, and 13 of 20 genes showed statistically different ex-
pression when comparing biopsies from normal individuals and
IgAN patients. Expression differences were seen in these genes
in biopsies of IgAN of differing clinical activities. Gene expres-
sion cluster analysis using the Ward method detailed disease-
and gene-related clusters. Detailed examination of the pro-
moter regions of the genes within two gene clusters revealed
common gene transcriptional regulatory protein-binding sites.
Conclusion. IgAN leads to significant changes in overall
mRNA transcription levels within the renal tissue, in addition
to gene-specific mRNA level changes. Disease-related patterns
of expression were identified and gene-specific clusters suggest
common mechanisms of transcriptional alteration.
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Immunoglobulin A (IgA) nephropathy (IgAN), first
described by Berger and Hinglais in the mid-1960s [1],
is characterized by significant deposition of IgA-rich im-
mune complexes in the glomeruli of the kidney [2]. IgAN
was initially believed to be uncommon and to have a
relatively benign progression, but demographic and longi-
tudinal studies have shown that IgAN is the most common
glomerular disease in the world and is a significant cause
of end-stage renal disease [3]. Mounting evidence suggests
that IgAN may have a genetic predisposition with respect
to its development and progression. There are clear ethnic
differences in the occurrence of IgAN. Molecular analysis
has shown an association with genetic polymorphisms in
the angiotensin-converting enzyme (ACE), the angioten-
sin II receptor 1, the T-cell receptor, and specific major
histocompatibility class II genes [4]. Recently, Ghavari et
al [5] demonstrated an association using a linkage analysis
to a gene(s) within chromosomal localization of 6q22-23
in familial IgAN. How or whether these genotypic features
relate to the important pathogenetic abnormalities in
IgA1 glycosylation remains unclear [6].
In this study, we used the technique of mRNA differ-
ential display to compare normal renal tissue to renal
biopsy material from patient biopsies with IgAN, mini-
mal change disease, and necrotizing crescentic glomeru-
lonephritis (NCGN). Using mRNA differential display
technology, we report here overall lower mRNA levels
relative to the total RNA isolated and identify a subset
of genes with altered expression in renal biopsy tissue
from IgAN patients that were largely confirmed by quan-
titative reverse transcription-polymerase chain reaction
(RT-PCR). Semi-quantitative renal disease activity scores
for the IgAN patients were determined for the biopsy
sample set and clustered with the gene expression levels
of the selected gene subset using the Ward cluster method.
Four clusters of patients primarily representing normal,
mildly active IgAN, moderately/severely active IgAN,
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and necrotizing crescentic glomerulonephritis biopsies
were identified based upon similar gene expression pat-
terns. Additionally, clustering delineated three distinct
gene clusters, and bio-informatic analysis of promoter
sequences of two genes from two of the gene clusters
revealed several promoter elements in common for the
genes within each cluster. The promoters in common
with different classes of gene clusters suggest a mecha-
nism for widespread change in gene expression and per-
haps thereby modulating disease activity in IgAN.
METHODS
Biopsy material and RNA
Tissue was obtained from clinical renal biopsies col-
lected at the University of North Carolina, Chapel Hill,
under a UNC Internal Review Board–approved proto-
col. Renal tissue was mounted in O.C.T. compound (Tis-
sue-Tek, Torrance, CA, USA) and stored at70C after
processing for pathologic diagnosis. Tissue was removed
from the OCT block by excision while frozen and pro-
cessed to total RNA using Trizol reagent (Life Technol-
ogy, Rockville, MD, USA). Tissue culture cells were
isolated using RNAStat 60 (Teltest, Inc., Friendswood,
TX, USA) following the manufacturer’s protocol.
For gene expression analysis, IgAN specimens were
compared to disease controls with minimal change dis-
ease (MCD), pauci-immune necrotizing crescentic glo-
merulonephritis (NCGN), and to normal control renal
tissue. Normal renal tissue samples were obtained by
needle biopsies of kidneys from traumatic death patients
or from normal margins after resection of renal cell carci-
nomas, and frozen before processing to replicate sample
conditions used for disease-related biopsies. Due to the
small RNA yields from each biopsy and significant RNA
amounts required for the differential display technique
used in these studies, RNAs were pooled. Seven normal
samples were divided into 3 pools, while single pools
were made from the 4 MCD patients and 4 NCGN pa-
tients. For IgAN clinical subgroups, biopsies from 4 mild,
4 moderate, and 4 severe patients were pooled to give
mild, moderate, and severe pooled sample groups. Clini-
cal activity of the IgAN samples was determined by the
simultaneous review of the patients’ clinic notes, pathol-
ogy reports of biopsy tissues, and renal function assessed
by the serum creatinine and the degree of hematuria
and proteinuria. Two members of our group (RJF and
JCJ) used this information to classify IgAN into 4 groups
of patients with mild, moderate, or severe disease and
a group of patients in remission. Classification of degree
of clinical disease activity was as follows: (1) mild disease
activity was defined as the presence of hematuria with1 g
proteinuria with normal renal function; (2) moderate
disease activity was defined as the presence of hematuria
with 1 g proteinuria and stable renal function; and
(3) severe disease activity was defined as progression to
renal insufficiency with hematuria and 1 g of protein-
uria. Patients were considered in remission if there was
no evidence of hematuria, 1 g of proteinuria, and no
evidence on renal biopsy of active glomerular inflamma-
tion (i.e., hypercellularity, necrosis, or cellular crescents).
Tissue from 4 patients with MCD and 4 patients with
pauci-immune necrotizing and crescentic glomerulone-
phritis served as disease controls. Realizing the funda-
mental bias caused by the pooling process we verified
by quantitative RT-PCR the expression levels of genes
of interest in a panel of additional biopsy RNA samples.
This expanded patient biopsy RNA panel consisted of
42 biopsy samples with 10 normal, 7 minimal change, 6
mildly active IgAN, 7 moderately active IgAN, 4 severely
active IgAN, and 8 NCGN, and included the RNA used
for differential display analysis.
Human cultured primary cells [umbilical arterial endo-
thelial (HUA), umbilical venous arterial (HUV), tubular
epithelial (EPI), and mesangial cells (Mes)] were ob-
tained from Clonetics (San Diego, CA, USA) and grown
per the company’s instructions. Growth arrest conditions
were growth to saturation density by extended cultiva-
tion, or treatment with 2 ng/mL human recombinant tumor
necrosis factor- (Collaborative Research, San Diego,
CA, USA) for specified times. Peripheral blood leuko-
cytes were isolated following removal of red blood cells
by hypotonic lysis as detailed previously [7].
mRNA expression analysis
Differential display expression analysis is a powerful
technique to determine altered expression of a large num-
ber of genes between a limited number of sample RNAs.
The method that we used is known as restriction endo-
nucleolytic analysis of differentially expressed sequences
(READS). READS is an enhanced differential dis-
play technology that visualizes nearly all mRNAs ex-
pressed in a given sample and allows the determination
of the differentially expressed sequences between samples
by visual or densitometric analysis [8]. cDNA from each
pool was generated with each of 12 possible different
heel primers using an adapter oligo-d(T) with the various
combinations of A, C, G, or T resulting from substitu-
tions at the last 2 base positions in each primer. Each
cDNA from a sample mRNA/primer combination was
digested independently with 8 different 6 base-recogni-
tion restriction enzymes (PstI, NcoI, SacI, XbaI, BsrGI,
XhoI, HindIII, MunI). Following adapter ligation, PCR
products were labeled during amplification using -33P-
ATP for finer band resolution. Product bands were re-
solved by sequencing gel separation. This combination
of primers and restriction enzymes resulted in approxi-
mately 80% of the expressed genes being visualized.
Autoradiographs of the gels were scanned visually for
expression differences and sequences of the differen-
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tially expressed bands were determined by coring the
gel, band elution, product amplification, and sequencing.
The READS processing and initial bioinformatics analy-
sis was performed at Gene Logic, Inc. (Gaithersburg, MD,
USA). The READS method is a proprietary process
covered by patents #6,010,850, #5,712,126, and #6,395,887.
Quantitative RT-PCR
Genes of interest identified by READSwere selected
for more detailed analysis using quantitative RT-PCR.
Primers and probes for TaqMan analysis were designed
using Primer Express 1.5 (Applied Biosystems, Foster
City, CA, USA) using company guidelines from se-
quence information from GenBank or EST databases.
For each gene, one-tenth to 1 ng of the individual biopsy
total RNA was analyzed on an ABI PRISM 7700 using
TaqMan EZ RT-PCR Core Reagent kit (Applied Bio-
systems). All TaqMan analysis was done using 3 pri-
mers PCR (forward and reverse primers with fluorescent
probe) to ensure specificity of signal. Fold-change analysis
was based on standardizing RNA levels by correcting for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
levels in the sample.
Statistical analysis and data mining
Overall differences between multiple groups were
tested using the non-parametric Kruskal-Wallis test and
analysis of variance. When distributions were not nor-
mally distributed, ranked values were used for analysis
of variance tests. Fold-change values for all genes except
protein disulfide isomerase and EST23476 were not nor-
mally distributed so that ranked values were used for
analysis of the other 18 genes. If there was an overall
difference between groups using these tests (P  0.05),
then Duncan’s multiple-range test was used to evaluate
differences between specific group means, while control-
ling the error rate from multiple comparisons. Fold-
change data determined by TaqMan Q-RT-PCR anal-
ysis was subjected to cluster analysis using the Ward’s
method [9] based upon the squared Euclidean distance
for each gene, in which the mean of the normal samples
was set to 0. The calculated results are plotted in Figure
3. DNA sequence analysis of promoter regions was per-
formed on sequences downloaded from GenBank using
Omiga software (Accelrys, Princeton, NJ, USA) and the
public web search site, TFBINF, for transcription factor
binding sites (website no longer on-line) [10].
RESULTS
Initial analysis of READS gels showed a significant
difference in overall signal intensity between gels derived
from normal renal tissue and from either the IgAN or
NCGN pools (Fig. 1A). A representative gel shows the
comparable signal intensity in normal samples in lanes
1 to 3, while IgAN with a range of clinical activities is
shown in lanes 4 to 6, and NCGN, in lane 7, show signifi-
cantly lower band intensities. RNA quantity and quality
of the total RNA from all of the samples were similar
(data not shown), thus eliminating RNA degradation as
a cause for this difference. These results suggested lower
levels of message present, while the predominant RNAs
in total RNA, the 28S and 18S ribosomal RNAs (rRNA),
were expressed at a constant level in all samples. To further
explore this difference, quantitative RT-PCR levels of
GADPH mRNAs in these samples were compared to 28S
rRNA levels. The ratios of the average levels of GAPDH
and 28S rRNA expression were calculated for the normal
and IgAN samples. One healthy control biopsy sample
was used as a standard and all other sample ratios were
divided by this initial ratio; then, the average for each
group was normalized to the normal sample average and
the standard deviations corrected proportionally. The
average and standard deviation of the normal and IgAN
biopsies are shown in Figure 1B and revealed that the
IgAN ratio was greater than 3-fold lower than the ratio
of average GAPDH and 28S rRNA levels from the nor-
mal control biopsy RNAs. This decrease was a statisti-
cally significant, P  0.01. Comparable results were seen
when similar comparisons were done with mitochondrial
DNA–dependent transcripts and 18S rRNA levels (data
not shown). As different RNA polymerases transcribe
rRNA and mRNAs, RNA polymerase I and II, respec-
tively, we examined the expression level of another RNA
polymerase II transcribed gene, -actin, and compared
its level to GAPDH. This comparison shows whether
the initial difference in the GAPDH/28S rRNA ratio is
due to lower expression of GAPDH only, or, alterna-
tively, if it is due to a systemic change in the RNA
polymerase II transcribed RNA expression. The fact that
a similar difference was seen with mitochondrial tran-
scripts argues the rRNA levels were not abnormally ele-
vated. Following similar averaging and ratio calculation
as performed for GAPDH and 28S rRNA, we found no
significant difference in GAPDH/-actin ratio for IgAN
samples compared to normal individuals (Fig. 1C). This
result shows that these two RNA polymerase II tran-
scribed “housekeeping” messages are similarly expressed
in IgAN and suggests the lower READS gel intensity
reflects a decrease in overall message synthesis in IgAN
tissue samples. To overcome this difference, 4- to 8-fold
larger amounts of product were loaded per lane, which
equalized the overall gel intensity in normal and disease-
derived samples and allowed the identification of differ-
entially expressed messages (Fig. 1D).
Initial identification of expression differences was
done by visual examination and 860 products were iden-
tified as potentially different between diseases and nor-
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Fig. 1. Molecular analysis of pooled biopsy samples. (A ) Representative restriction endonucleolytic analysis of differentially expressed sequences
(READS) gel showing analysis performed on normal tissue (lanes 1 to 3), immunoglobulin A nephropathy (IgAN) with clinical activity; mild
(lane 4), moderate (lane 5), severe (lane 6), and necrotizing crescentic glomerulonephritis (NCGN) (lane 7), using standard loading criteria.
Significantly lower message levels are seen in IgAN and NCGN samples. (B ) An average of the ratio of the relative expression levels of GAPDH
and 28S rRNA levels within the individual biopsy RNAs for normal and IgAN samples, as determined by quantitative real-time-polymerase chain
reaction (RT-PCR). The average of the normal samples was set to one. A statistically significant decrease in the ratio of the IgAN samples shows
decreased message levels. (C ) Similar averages of the ratios as in B, but for GAPDH and -actin mRNAs show no difference in gene levels in
normal versus IgAN samples. (D ) READS analysis on similar samples as in (A), with increased sample loading, shows comparable signal intensity.
PCR cores for re-amplification and sequencing were removed from PCR products following overlaying and alignment of the autoradiograph and
are seen as white spots in the middle of the autoradiographic bands.
mal samples, and for one or multiple clinical states for
the IgAN samples. From these 860, 175 non-homologous
messages were found based upon sequencing the re-
amplified and sequenced PCR bands excised from the
original gels (Fig. 1D). Examples of READS gels repre-
senting potentially differentially expressed fragments are
shown in Figure 2. Bands were removed, sequenced,
and subsequently identified as expressed sequence tags
(ESTs) 22402, 22972, and 22360. From the 175 sequences,
20 were selected for more detailed analysis by quantita-
tive RT-PCR based upon the largest intensity differ-
ences, disease specific changes, and expression variation
in samples of differing IgAN clinical activity (Table 1).
This list of genes includes six ESTs and known genes,
such as cathepsin D, napsin, TSC22, 45 kD megalin-
binding protein (MBP45K), a putative protease inhibitor
HE4, and the metalloprotease inhibitor TIMP1.
Statistical analysis of changes in gene expression was
performed for protein disulfide isomerase (PDI) and
EST23476 using untransformed fold-change values while
the fold-change values for other 18 genes were not nor-
Fig. 2. Representative restriction endonucleolytic analysis of differen-
tially expressed sequences (READS) analysis of specific genes identi-
fied as altered in disease. Differentially expressed fragments are identi-
fied by arrowheads, and subsequently were identified by sequencing
and denoted ESTs 22402, 22972, and 22360.
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mally distributed and ranked values were used. Seven-
teen of the 20 selected genes showed statistically signifi-
cant differences in comparing across all disease and
IgAN clinical activity groups. In comparisons of normal
biopsy expression levels with other diseases, 13 genes
were altered in IgAN, 7 in MCD, and 12 in NCGN,
with all the disease samples showing elevated expression
levels, while there were 3 genes different between MCD
and IgAN, 4 between MCD and NCGN, and 12 between
IgAN and NCGN (Table 1). Only prolyl 4-hydroxylase
alpha 1, napsin, and EST45396 were not altered in any
comparison (normal vs. disease, normal vs. IgAN of dif-
ferent clinical activity, or disease vs. disease). In normal
versus disease comparisons, two additional genes, TSC22
and EST 23476, were not altered, while MBP45k and
GA-binding transcription factor (GABP), were altered
in both normal versus disease and normal versus IgAN
clinical activity comparisons, and cathepsin D was al-
tered in all but the normal versus IgAN severe activity
comparisons.
The 13 genes elevated in IgAN relative to the nor-
mal controls were ESTs 22972, 22360, 22402, and 43719,
MBP45K, NYCO28, low density lipoprotein receptor-
related protein 2 (gp330, megalin), prolyl 4-hydroxylase
alpha-2 (prolyl2), GABP, cathepsin D, zinc29in4628
(zinc29), protein disulfide isomerase (PDI), and osteo-
blast-specific factor 2 (OSF2). Seven genes were altered
in minimal change biopsies and six altered in NCGN with
MPB45K, TIMP1, GABP, and cathepsin D common to
both groups, with gp330, prolyl2, and zinc29 additionally
altered in MCD, and EST22972 and HE4 altered in
NCGN. A few genes were selectively altered in a single
disease: PDI, EST43719, and OSF2 were elevated in
IgAN, and HE4 altered only in NCGN, while the re-
maining 12 genes from normal/disease comparisons were
altered in multiple diseases. Comparisons between dis-
ease groups showed 3 significant changes between MCD
and IgAN, 4 between MCD and NCGN, and 12 between
IgAN and NCGN. Most of these changes reiterate the
normal versus disease comparison and are the result of
a lack of a significant change of that disease type relative
to normal but altered expression of EST23476 (1.88- to
0.88-fold relative to normal) and TSC22 (0.88- to 0.38-
fold relative to normal) in the IgAN-NCGN comparison
was not seen with any other comparison. The functional
significance of these unique changes is unknown.
In comparisons of the normal control to the IgAN
biopsies of differing clinical activities, the genes showing
significant changes in the group as a whole are most
closely correlated with those with mild and moderate
activity, as 12 of the 13 genes were altered in both groups.
In biopsies of mild clinical activity, only OSF2 was not
altered, and in moderate clinical activity biopsies, EST
43719 was not changed. Significantly fewer changes were
seen in the severe activity biopsies with ESTs 22972,
22360, and 43719, GN01, prolyl2, and cathepsin D was no
longer significantly altered and with lower fold changes.
EST43719 elevated in IgANs of mild activity was the
only gene selectively over-expressed in a single clinical
activity group.
In an attempt to determine if any of these genes showed
disease-specific patterns of expression, the expression
levels of the 20 genes in each of the 42 biopsies were
subjected to the Ward method of cluster analysis and
the individual sample expression values plotted with the
associated clustering trees (Fig. 3). This analysis was done
regardless of the type of renal disease. When analyzed
for disease-related similarities, four distinct clusters were
identified, as shown by the trees on the right of the figure.
Examination of the patient population within each clus-
ter showed a predominant representation within each
individual group of normal, NCGN, mild IgAN, or mod-
erate/severe IgAN biopsies. The large “normal” cluster
contained all but one of the control biopsy samples but
additionally contained three NCGN (denoted ANCA),
two MCD, and three IgAN samples, while the remaining
IgAN and NCGN clusters were strongly represented by
patient samples with the predominant disease type or
clinical activity. It is of interest that the mild IgAN sub-
group was more closely related to the normal samples,
especially in the cluster II and III genes, and to NCGN
than to the more severe IgAN samples.
Cluster analysis also identified distinct gene subgroups
within the 20 genes examined based upon similar pat-
terns of gene expression. Three primary gene clusters
were revealed, with cluster I containing the genes GN01,
prolyl2, gp330, MBP45K, and ESTs 22360, 22972, and
22402; cluster II containing the largest number of genes
with HE4, TIMP1, PDI, napsin, TSC22, prolyl1, cathep-
sin D, E4tf1, zinc29in4628, and ESTs 45396, 23476, and
43719; and cluster III containing a single gene OSF2.
To determine if these clusters represented significantly
different expression profiles, the expression levels of rep-
resentative genes from each cluster were determined on
an expanded mRNA sample set containing additional
biopsies from each disease, isolated peripheral blood
leukocytes (PBLs), and cultured primary human endo-
thelial, epithelial, and mesangial cells. MBP45K and HE4
were examined as representatives of cluster I and II
expression profiles, respectively, and OSF2 for cluster
III. MBP45K expression was detected in all biopsy sam-
ples with elevated levels in MCD and IgAN samples
(Fig. 4A). Very low comparable expression levels were
found in all of the cultured cells but were higher in PBL
mRNAs (columns 63 to 68, Fig. 4B). Representative of
cluster II, HE4 expression was most elevated in patients
with NCGN and in tubular epithelial cells (Fig. 4 C
and D). The level of HE4 increased dramatically in the
growth-arrested epithelial cells induced by contact inhi-
bition (Fig. 4B, lanes 57 to 59). Cluster III, OSF2 expres-
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Fig. 3. Cluster analysis based on the expression levels of 20 representative restriction endonucleolytic analysis of differentially expressed sequences
(READS) genes in normal and diseased renal biopsy mRNAs. Relative expression levels were analyzed by the Ward method of clustering,
based upon the squared Euclidean distance for each gene in which the mean of the normal control samples was set to 0. Individual sample levels
are shown with elevated levels shown in increasing red color and lower levels shown in increasing intensities of green. Three gene clusters were
found, while 4 patient clusters representing normal, predominantly clinically mild activity immunoglobulin A nephropathy (IgAN), anti-neutrophil
cytoplasmic antibody (ANCA), and predominantly clinically moderate and severe IgAN. Individual samples were designated by the disease and
sample number with N prefix used for normal, ANCA for necrotizing crescentic glomerulonephritis (NCGN), MCD for minimal change disease,
and Mi, Mo-, Sev, or Un- with Ig used for mild, moderate, severe, or of unknown clinical activity for IgAN of different clinical activities.
sion was predominantly elevated in IgAN and arterial
endothelial cells (Fig. 4 E and F). While the expression
patterns in the biopsy RNAs were varied, their distinct
expression patterns in the PBLs and cultured cells sam-
ples clearly distinguishes these genes and affirms the
distinct clustering of the Ward method. Linear regression
analysis using two cluster I genes, MBP45K versus gp330,
and two cluster II genes, HE4 versus TIMP1, produced
R2 values of 0.48 and 0.69, respectively, showing the
coordinate expression of each cluster’s gene partners and
reaffirming the cluster analysis. Regression analyis of
cluster I with cluster II genes showed poor correlation
values (data not shown).
Changes in messenger RNA expression levels are ac-
complished through a combination of both the regulation
of transcription and modulation of message stability.
Transcriptional activity is regulated through availability
and/or activity of specific transcription factors. Thus,
based upon the correlation of expression levels of the
cluster genes detailed above, we examined upstream
gene sequences of cluster I genes HE4 and TIMP1, and
cluster II genes gp330 and MBP45K, to determine if
these genes had common known or cryptic transcrip-
tional regulatory elements in the promoter regions. The
genomic sequences were analyzed and compared using
bioinformatic tools. Binding sites for many transcription
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Fig. 4. mRNA expression levels of cluster I, II, and III genes in renal biopsies and cultured renal cells. Renal patient RNAs from normal, minimal
change disease (MC), immunoglobulin A nephropathy (IgAN), and necrotizing-crescentic glomerulonephritis (NCGN) patients are shown in (A,
C, and E ), while expression profiles in primary human umbilical cord venous endothelial cells (Huv), human umbilical cord arterial endothelial
cells (Hua), human renal epithelial cells (EP), human mesangial cells (Mes), and isolated peripheral blood leukocytes (PBLs) are seen in (B, D,
and F ). Expression of 45 kD megalin-binding protein (MBP45K) represented cluster I (A and C), HE4 represented cluster II genes (B and D),
and OSF2 was the only member of cluster III (C and F). Renal patient RNAs for normal (lanes 1 to 10), MC (lanes 11 to 17), IgAN (mild activity,
lanes 18 to 23, moderate clinical activity, lanes 24 to 30, and severe activity, lanes 31 to 34), and NCGN (lanes 35 to 42) are shown in (A, C, and
E), while expression profiles in Huvs (lanes 43 to 49), Hua (lanes 50 to 56), EP (lanes 57 to 59), Mes (lanes 60 to 62), and PBLs (normal donors,
lanes 63 and 64; IgAN patients, lanes 65 to 67, and one NCGN patient, lane 68). For Huv and Hua, cells were actively growing, treated with tumor
necrosis factor- for 1, 8, and 24 hours, or allowed to continue growing for 1, 4, and 5 days (saturation density), and are presented in that order.
For Epi, cells were actively growing, or after 3 and 5 days growth to confluence and growth arrest while the Mes cells were actively growing or
after 3 and 5 days growth to confluence and growth arrest.
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Fig. 5. Promoter regions of cluster I and clus-
ter II genes. Genomic sequences of cluster I
gp330 and MBP45K genes and cluster II HE4
and TIMP1 were analyzed for putative tran-
scription factor binding sites. Upstream se-
quences of the putative promoter regions genes
are shown (see Table 2 for description).
factors were found (Fig. 5 and Table 2). Of note, the
GABP and Stat3 binding sites were found in cluster I
genes, while MEF2, Oct1, XFD2, and many PBX1 bind-
ing sites were found in both cluster II genes HE4 and
TIMP1. E4Tf1 transcription factor, elevated in the mild
and moderate clinically active IgAN samples, binds to
the GABP transcriptional site, suggesting a potential
mechanism of altered gene expression.
DISCUSSION
Understanding the gene expression changes that occur
within an affected tissue during the development and
progression of a disease is the goal of current research,
but given sample amount requirements for analysis with
current technologies, few diseases and tissues have been
reasonable targets for such detailed studies. Cancer is an
exception and the molecular characterizations of mRNA
expression patterns using high-density gene chip arrays
of different breast cancers, lymphomas, and myelomas
have dissected and differentiated disease subtypes and
stages [11, 12]. These types of studies are the current
paradigm for molecular genetics. Due to the difficulty
of tissue access and abundance, dissection of renal dis-
ease has focused on the examination of in situ expression
of single genes such as vascular permeability factor [13],
C5a, [14], decay accelerating factor [15], and nitric oxide
synthase [16], using cumbersome technology such as in
situ mRNA hybridization.
We report here an examination of the mRNA expres-
sion profiles using mRNA differential display technology
[8] of renal biopsy tissue from patients with MCD, IgAN,
and NCGN. Dramatic expression changes were revealed
in scope and specificity. Initial observations revealed a
70 to 85% reduction in the overall message levels in
IgAN samples when compared to such standardization
genes as mitochondrial DNA-dependent transcripts, or
18S and 28S rRNAs. But levels of both glyceraldehydes-
3-phosphatase dehydrogenase (GAPDH) and -actin
mRNAs were expressed at comparable levels in both
normal or IgAN biopsies. GAPDH and -actin are tran-
scribed by RNA polymerase II, while the rRNAs are
transcribed by RNA polymerase I. Thus, a possible
mechanism for such general expression differences may
be explained by differences in RNA polymerase I and
RNA polymerase II activities.
From the 175 potential candidate genes in the ini-
tial analysis using the differential display technique of
READS, the majority of these genes were elevated in
disease. Of the 20 genes identified for further study, one
gene elevated in IgAN biopsy samples is EST 22402,
which has been identified as a human homolog of the
yeast Rsp5 gene. Rsp5 is an ubiquitin ligase for RNA
polymerase II [17]. Our working hypothesis is that up-
regulation in IgAN renal tissue of EST 22402 could mod-
ulate the ubiquitination of RNA polymerase II and lead
to decreased protein levels, which could ultimately result
in the decreased message levels seen here. Additionally,
of the 13 genes up-regulated in IgAN, changes in the
45 kD protein megalin-binding protein (MBP45K) and
gp330 levels may have direct metabolic consequences
due to the reported roles of gp330. The gp330 is the
protein identified as the Heyman nephritis antigen [18]
and is the multifunctional clearance receptor/low-density
lipoprotein receptor–related protein 2 precursor (mega-
lin) (glycoprotein 330), which binds to clusterin with high
Waga et al: Altered renal mRNA expression in IgA nephropathy1262
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affinity [19]. Elevation of gp330 could lower the tissue
or serum levels of clusterin, a condition that has been
associated with nephritic syndrome in renal disease [20].
Additionally, this molecule has been identified as a po-
tential drug receptor [21], as well as having the capacity
to bind and uptake molecules such as plasminogen, extra-
cellular matrix components, plasminogen activator-plas-
minogen activator inhibitor type I complex, apolipopro-
tein-e enriched beta-vldl, lipoprotein lipase, lactoferrin,
and calcium [22–25]. Furthermore, gp330 has been shown
in vitro to interact with thryoglobulin (tg) and mediate
transcytosis of the gp330 and tg complex through thyro-
cytes, thus blocking the induction of the thyroid hormone
T3, which is induced by tg endocytosis [26]. Modulation
of gp330 levels has the potential to change the functional
activity of a wide range of proteins linked to key meta-
bolic processes that may contribute to the development
of IgAN.
In NCGN, alteration of the protease/protease inhibi-
tor balance may be involved in the pathologic process
as elevated levels of the protease inhibitor TIMP1, the
putative protease inhibitor HE4, and the protease ca-
thepsin D were found in these biopsy RNAs. The aber-
rant activation of circulating neutrophils has been impli-
cated in NCGN [27], and modulation of the granule
protease by either heightened protease activity by addi-
tion of cathepsin D or by suppression of the protease
activity by addition of inhibitors could be involved in
the disease progression.
Another observation was that cluster analysis of the
quantitative RT-PCR derived gene expression data de-
lineated disease as well as gene specific clusters. Cluster-
ing by clinical diagnosis defined three clusters of samples
representing predominantly biopsy samples from normal
controls, NCGN, and two IgANs showing a predomi-
nance of either mild or moderate/severe disease activi-
ties. Only MCD samples did not show a distinct patient
cluster. This lack of minimal change patient clustering
is intellectually interesting but of unknown significance.
Furthermore, this cluster analysis also revealed specific
clusters of genes based upon related changes in the gene
expression patterns in the panel of biopsy RNAs. As the
genes in these clusters showed similar patterns of gene
regulation, a more detailed bioinformatic analysis of sev-
eral members of two classes revealed putative transcrip-
tion factor binding sites common among genes of the same
class. Specifically, GABP and Stat3 sites were found in
cluster I genes, g330 and MBP45K, and MEF2, Oct1, and
GABX consensus binding-site sequences were seen in
cluster II genes HE4 and TIMP1. GABP with Stat3 is
necessary for transcription of genes activated in the in-
flammatory process, such as interleukin-6 (IL-6). Changes
in expression of genes regulated by GABP, in combina-
tion with an elevation of the transcription factor E4TF1-47
reported here, which binds to the GABP site (CGGAAR)
[28], could account for the transcriptional changes and
altered mRNA levels shown in IgAN. While the poten-
tial of these genes in changing leukocyte mRNA expres-
sion is apparent, additional studies of the genes in other
clusters is needed to determine what role they have in
the disease related changes in leukocyte metabolism.
CONCLUSION
We report the large-scale analysis of mRNA expres-
sion patterns in renal biopsy tissues from patients with
minimal change disease, IgAN, and NCGN, and have
confirmed by quantitative RT-PCR statistically signifi-
cant changes in 17 of the original 20 READS analysis-
selected genes between all groups with 13 of these 17
altered between normal and IgAN samples. Character-
ization of the genes and clusters of genes with potentially
common regulatory processes may allow one to begin
dissecting the disease process occurring within the kid-
ney. The ultimate goal is to identify those gene expres-
sion changes directly involved in initiation and/or patho-
genesis and intervene with treatments at the appropriate
times to return altered gene expression to normal levels
[29]. While these studies have focused upon specific
changes in kidney tissue, recent studies on lupus have
characterized peripheral blood mononuclear cell expres-
sion profiles [30], and Mishra et al [31] have shown that
in vitro treatment of lupus T-cells with a histone deacetyl-
ation inhibitor, trichostatin A, resulted in normalized
levels of two over-expressed genes, interleukin-10 and
cell-surface ligand CD40 (CD154), and an under-
expressed gene, interferon-. It should be noted that
trichostatin A induced a wide range of gene expression
changes, but the effects on CD154, interleukin 10, and
interferon- hint that the overall approach may be viable.
Finally, we suggest that through the use of techniques
such as differential display and high-density gene chip
arrays on affected tissue(s), more detailed molecular
analyses will point to individual genes and/or gene
groups/clusters responsible for in situ pathologic pro-
cesses, and ultimately leading to targeting these genes
or modulation of their mRNA expression for therapy.
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